DYN
Dyne Therapeutics, Inc.
There isn't enough reported data to score DYN yet.
DYN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
DYN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
DYN PE Valuation
DYN has no meaningful PE right now: it lost money over the past year.
DYN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect DYN's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
DYN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.56 | +$0.12 |
| Q2 2026 | -$3.26 | +$0.62 |
| Q1 2026 | -$3.15 | +$0.46 |
| Q4 2025 | -$3.47 | -$0.10 |
| Q3 2025 | -$3.68 | -$0.11 |
| Q2 2025 | -$3.88 | -$0.28 |
| Q1 2025 | -$3.61 | +$0.37 |
| Q4 2024 | -$3.37 | +$0.58 |
DYN lost $3.56 per share over the past year, about the same as its loss the year before.
DYN Quarterly Revenue
DYN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$179.5M | -$88.3M |
| Q2 2026 | -$131.8M | -$37M |
| Q1 2026 | -$145.1M | -$38.3M |
| Q4 2025 | -$112.3M | -$26.9M |
| Q3 2025 | -$91.2M | -$16.3M |
| Q2 2025 | -$94.8M | -$39M |
| Q1 2025 | -$106.9M | -$28.1M |
| Q4 2024 | -$85.4M | -$50.3M |
DYN has burned cash in almost every quarter: −$569M over the past year, against −$378M the year before.
DYN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +641K shares |
| 1 year | +31% | +44.6M shares |
| 3 years | +205% | +126M shares |
| 5 years | +265% | +136M shares |
| Available history | +1362% | +175M shares |
DYN has 187M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
DYN Net Leverage
DYN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DYN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 23.7 | Neutral |
DYN's weekly RSI is 44 (neutral) and its Stochastic is 24 (neutral).
DYN PE vs Healthcare Sector
DYN has no meaningful PE right now: it lost money over the past year.
DYN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.2 | 5.1% above |
| 20 week MA | $20.6 | 17% below |
| 50 week MA | $19.0 | 11% below |
| 100 week MA | $16.4 | 3.5% above |
| 200 week MA | $18.7 | 9.1% below |
DYN's trend is mixed: it's above two of its five weekly moving averages, and 9.1% below its 200-week average.
DYN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.6 | $22.5 | -0.3% |
| 2021 | $22.5 | $12.9 | -43% |
| 2022 | $12.9 | $12.3 | -5% |
| 2023 | $12.3 | $13.3 | +8.6% |
| 2024 | $13.3 | $23.7 | +78% |
| 2025 | $23.7 | $20.0 | -16% |
| 2026 YTD | $20.0 | $17.0 | -15% |
DYN has finished lower in four of the last six years. It's down 15% so far in 2026.